COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION

摘要

FIELD: biotechnology.;SUBSTANCE: described is a combination of the obinutuzumab with a CD22 antibody-drug conjugate, which is anti-CD22-MC-vc-PAB-MMAE, for treating CD20 expressing cancer, wherein the anti-CD22 antibody in said conjugate contains a variable light chain domain of SEQ ID NO: 50 and heavy chain variable domain SEQ ID NO: 51.;EFFECT: invention extends the range of products for treating cancer, primarily a combination therapy for treating cancer types in which CD20 is expressed.;5 cl, 4 dwg, 6 tbl